REZZAYO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Spain, UK.

Active ingredients

The drug REZZAYO contains one active pharmaceutical ingredient (API):

1	Rezafungin UNII W1U1TMN677 - REZAFUNGIN ACETATE
	Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.).
	Read more about Rezafungin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REZZAYO Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
REZZAYO Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J02AX08		J Antiinfectives for systemic use → J02 Antimycotics for systemic use → J02A Antimycotics for systemic use → J02AX Other antimycotics for systemic use
Discover more medicines within J02AX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3063013
ES	Centro de información online de medicamentos de la AEMPS	1231775001
FR	Base de données publique des médicaments	67183313
IT	Agenzia del Farmaco	051002018
LT	Valstybinė vaistų kontrolės tarnyba	1098537
US	FDA, National Drug Code	70842-240